@article{TCR374,
author = {Faina Nakhlis and Mehra Golshan},
title = {Bevacizumab: where do we go from here in breast cancer?},
journal = {Translational Cancer Research},
volume = {1},
number = {1},
year = {2012},
keywords = {},
abstract = {Bevacizumab is a monoclonal antibody against circulating vascular endothelial growth factor A, which received accelerated FDA approval in 2008 for first line treatment of HER2-negative metastatic breast cancer. The initial approval was based on studies suggesting a progression-free survival and not overall survival. This observation served as the basis for looking into the use of bevacizumab as an adjunct to neoadjuvant chemotherapy in the treatment of HER2-negative breast cancer.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/374}
}